These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20514109)

  • 21. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians.
    Silverberg DS; Wexler D; Blum M; Schwartz D; Keren G; Sheps D; Iaina A
    Isr Med Assoc J; 2003 May; 5(5):337-9. PubMed ID: 12811950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
    Rostoker G; Griuncelli M; Loridon C; Couprie R; Benmaadi A; Bounhiol C; Roy M; Machado G; Janklewicz P; Drahi G; Dahan H; Cohen Y
    Am J Med; 2012 Oct; 125(10):991-999.e1. PubMed ID: 22998881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical review of the newer intravenous iron therapy options.
    Edwards JH
    Nephrol Nurs J; 2003 Feb; 30(1):70-3. PubMed ID: 12674953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.
    Kirschbaum B
    Clin Nephrol; 2002 Jun; 57(6):452-6. PubMed ID: 12078949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 30. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
    Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J
    J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
    Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients.
    Hsu SP; Chiang CK; Yang SY; Chien CT
    Nephron Clin Pract; 2010; 116(3):c207-16. PubMed ID: 20606481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of anemia in peritoneal dialysis patients.
    Lacson E; Diaz-Buxo JA
    Clin Nephrol; 2001 Dec; 56(6):415-27. PubMed ID: 11770793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R; Easom A; Juergensen P
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
    Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
    [No Abstract]   [Full Text] [Related]  

  • 38. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
    Kessler M; Salignac S; Aimone-Gastin I
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
    Nyvad O; Danielsen H; Madsen S
    Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of an anemia algorithm in chronic hemodialysis patients.
    Nhan J; Jensen L; McMahon A
    CANNT J; 2007; 17(3):48-58, 62-73; quiz 59-61, 74-6. PubMed ID: 17944348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.